The Lancet Diabetes & Endocrinology

AI summary · may contain errors

Early achievement of complete biochemical remission within 6 months in ectopic Cushing syndrome is linked to lower late complications and Cushing syndrome-related mortality, with adjusted HRs 0·55 and 0·49.

AI summary · may contain errors

Long-acting PTH analogues in chronic hypoparathyroidism show sustained PTH receptor activation with reduced needs for active vitamin D and calcium supplements, improving individualized management.

AI summary · may contain errors

Large-scale randomized evidence shows weight loss from incretin-based therapies is a disease-modifying strategy in several obesity-related conditions, with average weight loss of about 14–20% in people without diabetes.

AI summary · may contain errors

Once-weekly subcutaneous mazdutide in US adults with obesity or overweight produced least-squares bodyweight reductions at 32 weeks, reaching -18·1% with 16 mg versus -0·9% with placebo.

AI summary · may contain errors

Ketoacidosis occurred at an incidence of 2·43 per 1000 person-years during SGLT2 inhibitor treatment episodes in adults with type 2 diabetes across three Scandinavian countries.

AI summary · may contain errors

A modified Delphi process in type 2 diabetes reached consensus on a core set of 35 disease-modification outcomes across 11 domains, using two rounds with 233 and 79 participants.

AI summary · may contain errors

Once-weekly petrelintide in adults without type 2 diabetes produced a mean bodyweight reduction of -7·9% to -9·4% at 28 weeks versus -1·7% with placebo.

AI summary · may contain errors

Age- and sex-standardised type 2 diabetes prevalence in Mauritius rose from 14·7% in 1987 to 23·3% in 2009, then fell to 19·9% in 2021.

AI summary · may contain errors

Once-daily orforglipron in Japanese adults with obesity disease produced greater bodyweight loss at week 72 than placebo, with the largest mean change of -8·7% at 12 mg.

AI summary · may contain errors

In adults with recent-onset type 1 diabetes in the German Diabetes Study (n=600), unsupervised clustering identified three subtypes, including a mixed group linked to earlier β-cell decline by 6·1 years.

AI summary · may contain errors

GLP-1 receptor agonists and later multiagonist therapies have shifted obesity pharmacotherapy in the 2020s, with substantially greater efficacy, safety, and disease-modifying benefits than older agents.

AI summary · may contain errors

Hashimoto's thyroiditis is the leading cause of primary hypothyroidism in iodine-sufficient regions, progressing from euthyroid autoimmunity to subclinical or overt disease with variable clinical course.

AI summary · may contain errors

Low-dose interleukin-2 did not significantly preserve pancreatic β-cell function at month 12 in newly diagnosed type 1 diabetes, with C-peptide AUC ratio 1·06 (95% CI 0·56–2·01; p=0·85) versus placebo.

AI summary · may contain errors

In Japanese adults with type 2 diabetes, 52-week add-on oral orforglipron shows an acceptable safety profile, with treatment-emergent adverse events in 85% overall.

AI summary · may contain errors

Primary care-led diabetes models in people with type 2 diabetes are linked to improved glycaemic control, cardiometabolic outcomes, and health-care use across primary care and community settings.